Publications by authors named "Els Lierman"

15Publications

A monocentric retrospective study of 138 therapy-related myeloid neoplasms.

Ann Hematol 2018 Dec 10;97(12):2319-2324. Epub 2018 Sep 10.

Department of Laboratory Medicine, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3462-y
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3462-yDOI Listing
December 2018

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Ann Hematol 2015 Nov 23;94(11):1927-8. Epub 2015 Jul 23.

Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2451-7DOI Listing
November 2015

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Haematologica 2015 Jul 1;100(7):893-7. Epub 2015 May 1.

Center for Human Genetics, KU Leuven and University Hospitals Leuven, Belgium Department of Hematology, University Hospitals Leuven, Belgium

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.118299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486223PMC
July 2015

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Exp Hematol 2014 Apr 6;42(4):282-293.e4. Epub 2014 Jan 6.

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria; Ludwig Boltzmann Cluster Oncology, Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2013.12.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338611PMC
April 2014

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).

Haematologica 2011 Jun 17;96(6):922-6. Epub 2011 Feb 17.

Center for Human Genetics, K.U.Leuven, O&N1 Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2010.036558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105656PMC
June 2011

Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.

Expert Rev Anticancer Ther 2009 Sep;9(9):1295-304

Department of Molecular and Developmental Genetics VIB11, Center for Human Genetics, KULeuven, Campus Gasthuisberg O&N1, Herestraat 49-box 602, B-3000 Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.82DOI Listing
September 2009

TV6 and PDGFRB: a license to fuse.

Haematologica 2007 Feb;92(2):145-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.11187DOI Listing
February 2007

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.

Haematologica 2007 Jan;92(1):27-34

Department of Molecular and Developmental Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.10692DOI Listing
January 2007